Search Results - hematologic

3 Results

Sort By:

Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders

The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...

Published: 7/25/2024 | Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner

Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis

The zinc finger protein ZFP36L2 has been shown by the inventors to play an essential role in hematopoiesis, a process that is dysregulated in hematological cancers, anemia, and other conditions. Thus, ZFP36L2 has promise for use in a diagnostic test to detect abnormal hematopoiesis, or as a target for the development of therapeutics to treat abnormal...

Published: 4/8/2024 | Inventor(s): Deborah Stumpo, Perry Blackshear

Keywords(s): (4)r syndrome, anemia, Blood, C syndrome, CANCER, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, Chronic myelogenous leukemia, diagnostic, Diagnostic assay, diagnostic test, G syndrome, Hematologic, Hematopoiesis, Hypertelorism with esophageal abnormality and hypospadias, IAXXXX, IBXXXX, IXXXXX, Leukemia, lymphoma, N syndrome, Patent Category - Biotechnology, R(6) syndrome, R(7) syndrome, Syndrome X, therapeutic, Thrombocytopenia 2, Thrombocytopenia chromosome breakage, Tristetraprolin, W syndrome, W syndrome; Syndrome W, ZFP36L2, zinc finger

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology